Edwin DeJesus

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

Joel E. Gallant, Edwin DeJesus, José Ramón Arribas et al. · New England Journal of Medicine · 2006 · 879 citations

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 814 citations

Hepatology, Hepatitis C, Viral Hepatitis +9

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 735 citations · Full text

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 619 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +8

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 593 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +10